金双歧联合四联疗法对幽门螺杆菌感染的治疗

The efficacy of Golden Bifidobacterium combined with quadruple therapy on Helicobacter pylori infection

目的观察金双歧联合四联疗法根除幽门螺杆菌(H.pylori)的临床疗效。方法选取福建省立金山医院南院2015年8月1日至2017年8月1日300例H.pylori感染患者,随机分为A组(50例,采用雷贝拉唑、枸橼酸铋钾、克拉霉素和阿莫西林治疗)、B组(50例,在A组基础上联用金双歧治疗)、C组(50例,采用雷贝拉唑、枸橼酸铋钾、阿莫西林和呋喃唑酮治疗)、D组(50例,在C组基础上联用金双歧治疗)、E组(50例,采用雷贝拉唑、枸橼酸铋钾、呋喃唑酮和四环素治疗)、F组(50例,在E组基础上联用金双歧治疗)。观察各组患者的临床疗效及不良反应。结果 A、B、C、D、E和F组患者的H.pylori根除率按PP分析分别为81.4%、95.7%、82.2%、95.8%、97.9%和97.9%,而各组患者H.pylori根除率按ITT分析分别为70.0%、88.0%、74.0%、92.0%、92.0%和94.0%,A组和B组,C组和D组H.pylori根除率的PP分析和ITT分析比较差异有统计学意义(P<0.05);E组和F组根除率的PP分析和ITT分析比较差异无统计学意义(P>0.05)。A、B、C、D、E和F组的总不良反应率分别为30.2%、10.9%、31.1%、10.4%、53.2%和22.9%,其中A组和B组,C组和D组,E组和F组总不良反应率差异均有统计学意义(P<0.05)。结论金双歧联合四联疗法可提高H.pylori根除率,减少患者不良反应,可推荐用于H.pylori感染患者的根除治疗。

Objective To observe the clinical efficacy of Golden Bifidobacterium combined with quadruple therapy in the eradication of Helicobacter pylori（H.pylori）.Methods 300 patients with H.pyloriinfection in our hospital from August 1,2015 to August 1,2017 were randomly divided（n=50）into Group A（treated with Rabeprazole,Bismuth Potassium Citrate,Clarithromycin and Amoxicillin）,Group B（treated with the same treatment as group A combined with Golden Bifidobacterium）,Group C（treated with Rabeprazole,Bismuth Potassium Citrate,Amoxicillin and Furazolidone）,Group D（treated with the same treatment as group C combined with Golden Bifidobacterium,Group E（treated with Rabeprazole,Bismuth Potassium Citrate,Furazolidone and Tetracycline）,or Group F（treated with the same treatment as group E combined with Golden Bifidobacterium）respectively.The clinical efficacy and adverse reactions were observed.Results The H.pylori eradication rates in groups A,B,C,D,E and F were 81.4%,95.7%,82.2%,95.8%,97.9% and 97.9% respectively by PP analysis,and 70.0%,88.0%,74.0%,92.0%,92.0% and 94.0%respectively by ITT analysis.Significant difference in H.pylori eradication rate was seen between group A and B and between group C and D（Ps〈0.05）,but not between group E and F（P〉0.05）.The total rates of adverse reactions in groups A,B,C,D,E and F were30.2%,10.9%,31.1%,10.4%,53.2%and 22.9%respectively,with significant differences between groups A and B,groups C and D,and groups E and F（Ps〈0.05）.Conclusion Golden Bifidobacterium combined with quadruple therapy can improve the H.pylori eradication rate and reduce the adverse reactions,which can be recommended for the eradication of H.pylori.